Pharm
Vorapaxar
search
Vorapaxar
, Zontivity, Protease-Activated Receptor-1 Antagonist, PAR-1 Antagonist
Mechanism
Protease-Activated Receptor-1 Antagonist (PAR-1 Antagonist)
Inhibits
Platelet
aggregation for 4 weeks after dose
Indications
Not intended to be used alone
Limited to patients with very high cardiovascular risk
Adjunctive therapy to low dose
Aspirin
or
Clopidogrel
(
Plavix
)
Myocardial Infarction
Peripheral Arterial Disease
Contraindications
Prior
Cerebrovascular Accident
(CVA) or
Transient Ischemic Attack
(TIA)
Vorapaxar is associated with an increase risk of
Hemorrhagic CVA
in patients with prior cerebrovascular events
Combination with other antiplatelet agents (other than
Aspirin
or
Clopidogrel
)
Has not been studied with
Prasugrel
(
Effient
) or
Ticagrelor
(
Brilinta
)
Avoid with strong
CYP3A4
inhibitors or strong
CYP3A4
inducers
Drug Interactions
Strong
CYP3A4
inhibitors
Strong
CYP3A4
inducers
Precautions
Long half-life
No antidote in the case of severe bleeding
References
Morrow (2012) N Engl J Med 366(15):1404-13 [PubMed]
Type your search phrase here